• Acne
  • Actinic Keratosis
  • Aesthetics
  • Alopecia
  • Atopic Dermatitis
  • Buy-and-Bill
  • COVID-19
  • Case-Based Roundtable
  • Chronic Hand Eczema
  • Drug Watch
  • Eczema
  • General Dermatology
  • Hidradenitis Suppurativa
  • Melasma
  • NP and PA
  • Pediatric Dermatology
  • Pigmentary Disorders
  • Practice Management
  • Precision Medicine and Biologics
  • Prurigo Nodularis
  • Psoriasis
  • Psoriatic Arthritis
  • Rare Disease
  • Rosacea
  • Skin Cancer
  • Vitiligo
  • Wound Care

Poll

POLL: Which Recent FDA Update Was Most Exciting?

Author(s):

Dermatology Times Staff

Click here to answer this week's poll.

Baricitinib FDA Approved to Treat Alopecia Areata
Dupilumab FDA Approved for AD Patients 6 months to 5 years
TMB-001 Granted FDA Breakthrough Therapy Designation
FDA Grants Priority Review for Dupilumab sBLA for Adults with Prurigo Nodularis
Tapinarof Cream 1% is FDA Approved

Newsletter

Like what you’re reading? Subscribe to Dermatology Times for weekly updates on therapies, innovations, and real-world practice tips.

Subscribe Now!
Related Videos
Addressing Ongoing Benzoyl Peroxide and Benzene Updates at AAD 2025
Addressing Ongoing Benzoyl Peroxide and Benzene Updates at AAD 2025
Expert Insights Into L'Oréal’s Voluntary Recall of Benzoyl Peroxide Products
Expert Insights Into L'Oréal’s Voluntary Recall of Benzoyl Peroxide Products
Late-Breaking Data: Phase 3 Updates on Ruxolitinib Cream for Prurigo Nodularis
Late-Breaking Data: Phase 3 Updates on Ruxolitinib Cream for Prurigo Nodularis
Topical Corticosteroids: Potency, Vehicles, and Best Practices
Topical Corticosteroids: Potency, Vehicles, and Best Practices
Bunick Highlights Efficacy and Safety of JAK Inhibitors
Bunick Highlights Efficacy and Safety of JAK Inhibitors
FDA Approves Dupliumab for Prurigo Nodularis
FDA Approves Dupliumab for Prurigo Nodularis
Timber Pharmaceuticals Presents CI Study Data at EADV Congress
Timber Pharmaceuticals Presents CI Study Data at EADV Congress
Stephen Stripling, MD, FAAP, Discusses Study of Berdazimer Gel for Molluscum Contagiosum
Stephen Stripling, MD, FAAP, Discusses Study of Berdazimer Gel for Molluscum Contagiosum
How Infusion Centers Support Dermatology Research
How Infusion Centers Support Dermatology Research
What's Happening in the Vitiligo Pipeline?
What's Happening in the Vitiligo Pipeline?
Related Content
Exploring Off-Label Uses of Topical JAK Inhibitors
April 11th 2025

Exploring Off-Label Uses of Topical JAK Inhibitors

The Cutaneous Connection: Episode 31- Molecular Targeting of Psoriasis Biologics
September 23rd 2021

The Cutaneous Connection: Episode 31- Molecular Targeting of Psoriasis Biologics

Quoin Files US Patent Applications for Rare Disease Treatments
March 25th 2025

Quoin Files US Patent Applications for Rare Disease Treatments

The Cutaneous Connection
September 2nd 2021

The Cutaneous Connection: Episode 30- Impact of the JAK Inhibitor Approval Delays

L'Oréal Issues Voluntary Recall of Benzoyl Peroxide Products Over Benzene Concerns
March 10th 2025

L'Oréal Issues Voluntary Recall of Benzoyl Peroxide Products Over Benzene Concerns

Medicus Reports Promising Interim Results for Non-Invasive BCC Treatment
March 10th 2025

Medicus Reports Promising Interim Results for Non-Invasive BCC Treatment

© 2025 MJH Life Sciences

All rights reserved.